Amgen (AMGN) Q1 2024: Rare Disease Sales Top $950M as Meritide Phase III Plans Accelerate
Rare disease sales broke through $950 million, underscoring Amgen’s diversification and pipeline momentum. The company’s strategic focus on pipeline execution, especially for obesity candidate Meritide and next-gen oncology launches, signals a clear intent to scale growth levers beyond legacy therapies. Elevated R&D investment and operational integration of Horizon assets set the stage for a multi-pillar expansion story into the next decade.
Summary
- Rare Disease Expansion: Rare disease portfolio delivered significant growth, validating Amgen’s diversification strategy.
- Pipeline Prioritization: Meritide and tarlatumab advances highlight a focus on high-impact, late-stage assets.
- Capital Allocation Shift: R&D ramp and manufacturing investments underscore a long-term growth orientation.
Business Overview
Amgen is a global biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. The company generates revenue through four therapeutic pillars: general medicine (including cardiovascular and bone health), oncology, inflammation, and rare disease. Major segments include branded biologics, biosimilars, and an expanding rare disease portfolio, with recent growth fueled by the Horizon Therapeutics acquisition.
Performance Analysis
Amgen posted robust revenue gains, driven by 25% volume growth and the full integration of Horizon-acquired rare disease assets. The rare disease segment contributed over $950 million in Q1, a 14% year-over-year increase, with brands like Tepezza, Krystexxa, and Uplizna posting double-digit gains. General medicine, led by Repatha and Evenity, also saw strong double-digit growth, offsetting price pressures from higher rebates and payer mix adjustments.
Oncology performance was more mixed, as legacy drugs like Enbrel declined, but innovative therapies such as Blincyto and Tarlatumab (pending approval) gained traction. Operating expenses increased sharply, up 33% year-over-year, reflecting stepped-up R&D investment and Horizon integration costs. Operating margin held at 43%, consistent with prior guidance, but free cash flow dipped due to a planned $800 million tax deposit.
- Rare Disease Outperformance: Rare disease sales now represent a material share of total revenue, signaling successful pipeline-to-commercial execution.
- General Medicine Volume Surge: Repatha and Evenity delivered record quarters, reinforcing the company’s ability to scale core franchises despite price erosion.
- R&D Spend Acceleration: Elevated R&D investment, up 25%+ for 2024, reflects confidence in advancing late-stage pipeline assets.
Amgen’s diversified growth is increasingly visible, but margin and cash flow pressures from integration and R&D investment will be key watchpoints for the remainder of 2024.
Executive Commentary
"We have a number of products across general medicine, oncology, and inflammation that have strong momentum and still plenty of room to grow...Our newest pillar of growth, rare disease, contributed nearly a billion dollars of sales in the quarter."
Bob Bradway, CEO
"Strong execution resulted in sales growth of 22% year over year, with robust volume growth across the four therapeutic pillars of our business...Our integration of the Legacy Horizon business continues to progress well, with that portfolio generating $914 million in the quarter."
Myrtle Gordon, Chief Financial Officer
Strategic Positioning
1. Rare Disease as a Growth Engine
The rare disease portfolio is emerging as a central pillar, with nearly $1 billion in quarterly sales and 14% year-over-year growth. Amgen is leveraging its global footprint to accelerate launches in new geographies and indications, especially for Tepezza, Krystexxa, and Uplizna. The integration of Horizon assets is on track, with synergy targets and international expansion set to unlock further upside.
2. Obesity and Cardiometabolic Pipeline Bet
Meritide, Amgen’s lead obesity candidate, is advancing to Phase III with management signaling high confidence in its differentiated profile. The company is prioritizing manufacturing scale and device innovation (auto-injector, monthly or less frequent dosing) to compete in what is likely to be a multi-billion dollar category. The decision to halt AMG 786 development signals a disciplined focus on only the most promising assets.
3. Oncology Innovation and Next-Gen Launches
Tarlatumab, a first-in-class T-cell engager for small cell lung cancer, awaits imminent FDA decision and is already in three Phase III trials for earlier-line settings. Amgen is also advancing other bispecifics and targeted therapies in solid tumors, aiming to replicate the success of Blincyto in hematology within solid tumor indications.
4. R&D and Manufacturing Scale-Up
R&D investment is being ramped up, with 2024 guidance raised to 25% growth over prior year, reflecting a pipeline-heavy capital allocation strategy. Amgen is also expanding manufacturing capacity, including new sites in Ohio and North Carolina, to support future launches and large-scale supply needs, particularly for biotherapeutics and obesity candidates.
5. Biosimilars and Global Expansion
Biosimilars remain a strategic lever, with new launches (including a Keytruda biosimilar) and positive regulatory milestones (Stelara biosimilar) broadening the portfolio. This segment provides a hedge against branded pricing headwinds and supports international growth, especially in oncology and immunology.
Key Considerations
Q1 marks a pivotal quarter as Amgen transitions from legacy biologics to a multi-pillar growth model, underpinned by rare disease, obesity, and oncology innovation. The integration of Horizon, aggressive pipeline investment, and a focus on manufacturing readiness for scale-up are setting the stage for long-term expansion.
Key Considerations:
- Rare Disease Leverage: Horizon integration appears ahead of schedule, with synergy realization and international launches supporting the growth thesis.
- Obesity Market Entry Risk: Meritide’s Phase III path and manufacturing scale will determine Amgen’s ability to compete with entrenched GLP-1 incumbents.
- Pipeline Concentration: Heavy capital allocation to late-stage assets increases execution risk if key readouts disappoint or timelines slip.
- Margin Compression Watch: Elevated R&D and integration costs will pressure near-term margins, though management expects improvement over the next three quarters.
Risks
Amgen faces material risks from pipeline execution, especially in obesity and oncology, where clinical setbacks or delays could undermine growth assumptions. Integration of Horizon assets brings synergy realization and operational complexity risk. Margin pressure from R&D ramp and pricing headwinds in legacy franchises are watchpoints. Regulatory or manufacturing setbacks, especially for high-profile launches, could impact revenue growth and investor confidence.
Forward Outlook
For Q2 2024, Amgen guided to:
- Total revenue in the range of $32.5 billion to $33.8 billion for full year
- Non-GAAP EPS between $19.00 and $20.20 for full year
Management highlighted several factors that shape the forward outlook:
- R&D expenses to increase approximately 25% YoY, reflecting pipeline confidence
- Operating margin expected to improve over the next three quarters as integration and scaling efficiencies materialize
Takeaways
Amgen’s Q1 results reinforce its transition to a diversified, pipeline-driven growth model, with rare disease and obesity leading the next wave.
- Rare Disease Momentum: Near $1 billion in quarterly rare disease sales validates the Horizon acquisition and international launch strategy.
- Obesity Pipeline Execution: Meritide’s Phase III readiness and manufacturing scale-up will be the main swing factor for multi-year growth.
- Investor Focus: Watch for clinical data readouts, margin recovery, and further clarity on biosimilar launches in 2024.
Conclusion
Amgen’s Q1 marks a turning point as rare disease and pipeline assets take center stage, offsetting legacy pressures and setting up for multi-year growth. Sustained R&D investment and operational integration will be critical to realizing the full value of its diversified portfolio.
Industry Read-Through
Amgen’s rare disease and obesity pipeline progress signals intensifying competition for both legacy and emerging biopharma players. The company’s push into large-scale obesity markets with a differentiated candidate and robust supply chain could reshape the competitive landscape, especially for GLP-1 incumbents. Horizon integration and biosimilar expansion highlight the importance of operational scale and global reach for sustainable growth in specialty pharma. Investors should expect further consolidation and pipeline prioritization across the sector as R&D and manufacturing scale become decisive levers.